$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000159075019000032 Filed on May 09, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$2.514M	$372.0K	$4.784M
YoY Change	15.22%	-92.22%	935.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.860M	$3.360M	$2.990M
YoY Change	7.12%	12.37%	-8.84%
% of Gross Profit
Research & Development	$8.599M	$8.751M	$6.413M
YoY Change	2.67%	36.46%	55.66%
% of Gross Profit
Depreciation & Amortization	$100.0K	$73.00K	$69.00K
YoY Change	0.0%	5.8%	-31.0%
% of Gross Profit
Operating Expenses	$11.46M	$12.11M	$9.403M
YoY Change	3.74%	28.77%	27.05%
Operating Profit	-$8.942M	-$11.74M	-$4.619M
YoY Change	0.91%	154.08%	-33.43%
Interest Expense	$50.00K	$110.0K	-$40.00K
YoY Change	-66.67%	-375.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$275.0K	$339.0K	$167.0K
YoY Change	-23.82%	102.99%	456.67%
Pretax Income	-$8.900M	-$11.63M	-$4.660M
YoY Change	2.18%	149.57%	-33.24%
Income Tax
% Of Pretax Income
Net Earnings	-$8.896M	-$11.63M	-$4.661M
YoY Change	2.09%	149.5%	-33.22%
Net Earnings / Revenue	-353.86%	-3126.08%	-97.43%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.300M	-$5.646M	-$2.633M
COMMON SHARES
Basic Shares Outstanding	30.93M shares	30.92M shares	30.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.90M	$51.00M	$78.10M
YoY Change	-42.46%	-34.7%	43.83%
Cash & Equivalents	$24.01M	$18.20M	$78.10M
Short-Term Investments	$19.90M	$32.80M
Other Short-Term Assets	$3.800M	$3.200M	$3.400M
YoY Change	0.0%	-5.88%	41.67%
Inventory
Prepaid Expenses
Receivables	$325.0K	$6.000K	$4.809M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$48.08M	$54.21M	$86.35M
YoY Change	-40.8%	-37.22%	51.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$652.0K	$691.0K	$589.0K
YoY Change	6.19%	17.32%	-1.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	0.0%	-80.62%
Total Long-Term Assets	$702.0K	$741.0K	$639.0K
YoY Change	5.72%	15.96%	-25.26%
TOTAL ASSETS
Total Short-Term Assets	$48.08M	$54.21M	$86.35M
Total Long-Term Assets	$702.0K	$741.0K	$639.0K
Total Assets	$48.78M	$54.95M	$86.99M
YoY Change	-40.43%	-36.83%	50.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.232M	$517.0K	$760.0K
YoY Change	167.25%	-31.97%	-32.44%
Accrued Expenses	$3.946M	$3.044M	$3.377M
YoY Change	11.66%	-9.86%	-19.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.000M	$3.300M
YoY Change	1233.33%
Total Short-Term Liabilities	$9.148M	$6.860M	$4.137M
YoY Change	113.54%	65.82%	-43.17%
LONG-TERM LIABILITIES
Long-Term Debt	$6.200M	$7.100M	$10.00M
YoY Change	-36.73%	-29.0%	334.78%
Other Long-Term Liabilities	$0.00	$41.00K	$131.0K
YoY Change	-100.0%	-68.7%	-24.71%
Total Long-Term Liabilities	$0.00	$41.00K	$131.0K
YoY Change	-100.0%	-68.7%	-24.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.148M	$6.860M	$4.137M
Total Long-Term Liabilities	$0.00	$41.00K	$131.0K
Total Liabilities	$15.35M	$13.99M	$14.29M
YoY Change	7.94%	-2.04%	45.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$146.8M	-$137.9M	-$98.25M
YoY Change	37.26%	40.38%	32.67%
Common Stock	$310.0K	$309.0K	$302.0K
YoY Change	1.31%	2.32%	41.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$33.44M	$40.96M	$72.71M
YoY Change
Total Liabilities & Shareholders Equity	$48.78M	$54.95M	$86.99M
YoY Change	-40.43%	-36.83%	50.52%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$8.896M	-$11.63M	-$4.661M
YoY Change	2.09%	149.5%	-33.22%
Depreciation, Depletion And Amortization	$100.0K	$73.00K	$69.00K
YoY Change	0.0%	5.8%	-31.0%
Cash From Operating Activities	-$7.170M	-$11.81M	-$7.361M
YoY Change	58.98%	60.43%	-10.05%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	$37.00K	$95.00K
YoY Change	-66.67%	-61.05%	115.91%
Acquisitions
YoY Change
Other Investing Activities	$13.05M	-$2.780M	$0.00
YoY Change	-139.79%		-100.0%
Cash From Investing Activities	$13.03M	-$2.820M	-$95.00K
YoY Change	-139.63%	2868.42%	-107.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$138.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-40.00K	$218.0K	$38.11M
YoY Change	-101.48%	-99.43%	-2.56%
NET CHANGE
Cash From Operating Activities	-7.170M	-$11.81M	-$7.361M
Cash From Investing Activities	13.03M	-$2.820M	-$95.00K
Cash From Financing Activities	-40.00K	$218.0K	$38.11M
Net Change In Cash	5.820M	-$14.41M	$30.66M
YoY Change	-116.78%	-147.01%	-4.7%
FREE CASH FLOW
Cash From Operating Activities	-$7.170M	-$11.81M	-$7.361M
Capital Expenditures	-$30.00K	$37.00K	$95.00K
Free Cash Flow	-$7.140M	-$11.85M	-$7.456M
YoY Change	61.54%	58.88%	-9.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30931219	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	376000	USD
CY2019Q1	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	485000	USD
CY2018Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	33000	USD
CY2019Q1	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	27000	USD
CY2018Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2019Q1	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2018Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1129000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	571000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	270000	USD
CY2019Q1	mgen	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding	0.04
CY2019Q1	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	2804572	shares
CY2019Q1	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1191000	USD
CY2018Q1	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	47000	USD
CY2019Q1	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	1000	USD
CY2019Q1	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
CY2018Q4	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	500000	USD
CY2019Q1	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	300000	USD
CY2019Q1	mgen	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	2	renewal_term
CY2019Q1	mgen	License Fee Expense Milestone Reached LicenseFeeExpenseMilestoneReached	700000	USD
CY2018Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	367000	USD
CY2019Q1	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	449000	USD
CY2018Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2019Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	517000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	182000	USD
CY2018Q1	us-gaap	Accretion Expense AccretionExpense	96000	USD
CY2019Q1	us-gaap	Accretion Expense AccretionExpense	94000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3868000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3044000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	246000	USD
CY2018Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	124000	USD
CY2019Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	90000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3090000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3159000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177335000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	178570000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	790000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1018000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	790000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1018000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2912000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4493000	shares
CY2018Q4	us-gaap	Assets Assets	66147000	USD
CY2019Q1	us-gaap	Assets Assets	54950000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	65370000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	54209000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4661000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11624000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29900000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	32800000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29900000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	32800000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47441000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78099000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32606000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18195000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30658000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14411000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	51000000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1022705	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30839463	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30921219	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30839463	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30921219	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	308000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	309000	USD
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2019Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	69000	USD
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	57000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1704000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	786000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9600000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M29D
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2990000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3357000	USD
CY2018Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019Q1	us-gaap	Liabilities Liabilities	13994000	USD
CY2018Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2019Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-146000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-54000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3353000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-18000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	365000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-849000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	521000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	298000	USD
CY2018Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	209000	USD
CY2019Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	232000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	112000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	136000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2019Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2018Q4	us-gaap	Liabilities Liabilities	14803000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66147000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54950000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6733000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6860000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	10000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3667000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2333000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8004000	USD
CY2019Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	7093000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38114000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	218000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-95000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2820000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7361000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11809000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-4661000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-11629000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4661000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11629000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	167000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	339000	USD
CY2018Q4	us-gaap	Notes Payable NotesPayable	10298000	USD
CY2019Q1	us-gaap	Notes Payable NotesPayable	10392000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2294000	USD
CY2019Q1	us-gaap	Notes Payable Current NotesPayableCurrent	3299000	USD
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	9403000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	12108000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4619000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11736000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	580000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	303000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	277000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	174000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	113000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	5000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	66000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23783000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	95000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000	USD
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2865000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3164000	USD
CY2018Q1	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	110000	USD
CY2019Q1	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	84000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21000000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	112000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3817000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3850000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	691000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6413000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8751000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126296000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137925000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4784000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	372000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	790000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1018000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	902720	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1233578	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4182404	shares
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	29875000	USD
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	32844000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	110000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	84000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37845000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	112000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	38510000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	72706000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	51344000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	40956000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26483112	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30886085	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001590750-19-000032-index-headers.html	Edgar Link	pending
0001590750-19-000032-index.html	Edgar Link	pending
0001590750-19-000032.txt	Edgar Link	pending
0001590750-19-000032-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-20190331.xml	Edgar Link	completed
mgen-20190331.xsd	Edgar Link	pending
mgen-20190331_cal.xml	Edgar Link	unprocessable
mgen-20190331_def.xml	Edgar Link	unprocessable
mgen-20190331_lab.xml	Edgar Link	unprocessable
mgen-20190331_pre.xml	Edgar Link	unprocessable
mgen-q12019x10q.htm	Edgar Link	pending
mgen-q12019xex101yale.htm	Edgar Link	pending
mgen-q12019xex311.htm	Edgar Link	pending
mgen-q12019xex312.htm	Edgar Link	pending
mgen-q12019xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2019 Q2 Form 10-Q Financial Statement

#000159075019000032 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2019 Q2 Form 10-Q Financial Statement

#000159075019000032 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn